Yuwei Yuan, Tian Zeng, Anbo Gao, Yang Guan, Qun-Feng Zhang, Yukun Li, Hui Tan, Juan Zou
{"title":"Utilization of DNA Replication factor MCM2 by Cancer.","authors":"Yuwei Yuan, Tian Zeng, Anbo Gao, Yang Guan, Qun-Feng Zhang, Yukun Li, Hui Tan, Juan Zou","doi":"10.2174/0115680096349638250117101910","DOIUrl":null,"url":null,"abstract":"<p><p>MCM2 belongs to the microchromosome maintenance [MCM] family and plays an essential role in initiating DNA replication as well as maintaining normal cellular cycle functions. Recent research indicates that there is the abnormal expression of MCM2 in various cancers, such as breast, cervical, ovarian, lung, hepatocellular carcinoma, nephroblastoma, prostate, and pancreatic cancers, where it shows a strong link to tumorigenesis, growth, invasion, migration, and adverse prognosis. Thus, MCM2 could serve as a significant biomarker for the early identification, diagnosis, and prognostic evaluation of multiple cancers. In addition, targeting MCM2 expression may open new possibilities for a full range of cancer treatments. In this paper, the protein structure, physiological function, and carcinogenic mechanism of MCM2 were reviewed.</p>","PeriodicalId":10816,"journal":{"name":"Current cancer drug targets","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current cancer drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680096349638250117101910","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
MCM2 belongs to the microchromosome maintenance [MCM] family and plays an essential role in initiating DNA replication as well as maintaining normal cellular cycle functions. Recent research indicates that there is the abnormal expression of MCM2 in various cancers, such as breast, cervical, ovarian, lung, hepatocellular carcinoma, nephroblastoma, prostate, and pancreatic cancers, where it shows a strong link to tumorigenesis, growth, invasion, migration, and adverse prognosis. Thus, MCM2 could serve as a significant biomarker for the early identification, diagnosis, and prognostic evaluation of multiple cancers. In addition, targeting MCM2 expression may open new possibilities for a full range of cancer treatments. In this paper, the protein structure, physiological function, and carcinogenic mechanism of MCM2 were reviewed.
期刊介绍：
Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
